Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

HBeAg 양성 산모의 분만 직후 HBV-DNA 수치에 따른 주산기 예방조치의 결과

The outcome of perinatal prophylaxis for HBeAg positive mothers according to the maternal HBV-DNA levels at the delivery time

  • 정온 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김종현 (가톨릭대학교 의과대학 소아과학교실)
  • Jeong, On (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jong-Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 투고 : 2007.02.06
  • 심사 : 2007.03.14
  • 발행 : 2007.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : B형 간염 바이러스 주산기 감염은 현재 감소하고 있지만 HBeAg 양성 산모로부터 분만된 신생아의 10%는 예방조치에도 불구하고 보유자가 된다. 비록 예방조치 실패의 원인이 아직 불확실하나 산모의 분만시 HBV-DNA 수치의 중요성이 제시되고 있다. 본 연구는 산모의 분만시 HBV-DNA 수치가 주산기 예방조치 결과의 유용한 예측인자임을 확인하기 위하여 시행하였다. 방 법 : 주산기 예방조치의 결과를 이미 알고 있는 29명의 HBeAg 양성 산모를 선정하였다. 산모의 HBV-DNA 양을 측정하기 위하여 WHO International Standard For Hepatitis B Virus DNA For NAT Assay를 이용한 정량적 PCR을 시행하였다. 결 과 : 주산기 예방조치 실패군 산모의 로그 HBV-DNA 수치가 성공군 산모의 수치보다 유의하게 높았다(7.99 vs. 6.72, P=0.015). 주산기 예방조치 결과를 예측할 수 있는 산모의 HBV-DNA 수치의 기준은 $2.83{\times}10^7$ 개체/mL(100 pg/mL)로 정할 수 있었는데, 산모의 HBV-DNA 수치가 기준치 미만인 16명 중 예방조치에 실패한 경우는 없었으며(0%), 기준치 이상인 경우는 13명 중 5명(38.5%)이 실패하였다. 결 론 : 현재의 예방조치법으로는 분만시 높은 HBV-DNA 수치를 가지는 산모의 주산기 예방조치 결과는 좋지 않을 가능성이 높다. 따라서 주산기 예방조치의 실패율을 낮추기 위해서는 이러한 위험요인이 있는 경우에 보다 강력한 방법을 적용시켜야 하겠다.

Purpose : Perinatal hepatitis B viral infection is decreasing; however, 10% of babies to HBeAg positive mothers still become chronic carriers despite perinatal prophylaxis. Although, the cause of prophylaxis failure is still unclear, an importance of maternal HBV-DNA level at the delivery time has been suggested. This study was established to certify if it would be a useful predictable factor for the outcome of perinatal prophylaxis. Methods : Twenty-nine HBeAg positive mothers whose babies had known outcomes of prophylaxis were selected. To determine the amount of maternal HBV-DNA, a quantitative PCR was performed with the WHO International Standard for HBV DNA NAT assays. Results : The mean logarithm HBV-DNA level of mothers with failed outcomes was significantly higher than that of mothers with succeessful outcomes (7.99 vs. 6.72, P=0.015). The predictable maternal HBV-DNA cut-off level to prophylaxis outcome was $2.83{\times}10^7copies/mL$ (100 pg/mL). None out of the case 16 (0%) who had below this level, and 5 out of 13 (38.5%) who had above this level of maternal HBV-DNA failed in perinatal prophylaxis. Conclusion : Mothers with higher levels of HBV-DNA at delivery time would be prone to a worse outcome of prophylaxis using the conventional approach. Perinatal prophylaxis failure rate can be reduced, if we try to introduce more potent prophylactic treatment into the cases with this risk factor.

키워드

과제정보

연구 과제 주관 기관 : 가톨릭중앙의료원

참고문헌

  1. Moradpour D, Wands JR. Understanding hepatitis B infection. N Engl J Med 1995;332:1092-3 https://doi.org/10.1056/NEJM199504203321610
  2. Choung JM, Kim JC, Eun SH, Hwang PH, Nyhambat B, Kilgore P, et al. Study on vaccination state in children: Jeonbuk Province, 2000. J Korean Pediatr Soc 2002;45: 1234-40
  3. Chang JY, Cheong SJ, Kim SK, Son BK, Hong YJ, Hong KS. Positive rate of HBsAg in school children in Incheon area. Korean J Pediatr Infect Dis 2003;10:153-8 https://doi.org/10.14776/kjpid.2003.10.2.153
  4. The Office for Health and Medical Care Policy in The Ministry of Health & Welfare, Division of Chronic Disease Surveillance in Korea Centers for Disease Control and Prevention. 2005 National Health and Nutrition Survey in Korea: Medical Examination Survey. Kwacheon: The Ministry of Health & Welfare, 2006:204
  5. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of carrier state. J Infect Dis 1985; 151:599-603 https://doi.org/10.1093/infdis/151.4.599
  6. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994;44:144- 51 https://doi.org/10.1002/jmv.1890440206
  7. Kim JH, Kang JH, Oh CK. Immune responses and efficacy of hepatitis B vaccine in neonates born from hepatitis B carrier mothers: focus on HBV-DNA. J Korean Pediatr Soc 1998:41:1498-508
  8. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, Mclachlan A. Is a function of the secreted hepatitis B eantigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-603
  9. Kim JH, Pyo CW, Koh DK, Hur JK, Kang JH, Kim TG. Alteration of the influences of HLA classes I and II alleles on the perinatal hepatitis B virus infection after immunoprophylaxis in Korean children. Hepatol Res 2006;35:118-26 https://doi.org/10.1016/j.hepres.2006.03.004
  10. Kim JH, Pyo CW, Hur SS, Kim YK, Kim TG. Influences of IL-1B, IL-1RN, TNFA, and TNFB alleles on chronic HBV infection and perinatal infections of hepatitis B virus after immunoprophylaxis. Human Immunol 2003;64 Suppl 10:143
  11. Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702 https://doi.org/10.1016/0264-410X(94)00080-7
  12. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-7 https://doi.org/10.1002/hep.510300511
  13. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-27 https://doi.org/10.1002/jmv.10206
  14. Kim JH, Koh DK, Hur JK, Kang JH, Nainan OV, Margolis HS. The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection. Korean J Hepatol 2005;11:320-8
  15. Ip HMH, Lelie PN, Wong VCW, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989;i:406-9
  16. Wheeley SM, Jackson PT, Boxall EH, Tarlow MJ, Gatrad AR, Anderson J, et al. Prevention of perinatal transmission of hepatitis B virus(HBV): a comparison of two prophylactic schedules. J Med Virol 2001;35:212-5 https://doi.org/10.1002/jmv.1890350312
  17. Lin HH, Chang MH, Chen DS, Sung JL, Hong KH, Young YC, et al. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysisof prophylaxis failure. Vaccine 1991;9:457-60 https://doi.org/10.1016/0264-410X(91)90135-S
  18. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WCJ, Gerards LJ, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15:1624-30
  19. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as a risk. Clin Infect Dis 1998;27:100-6 https://doi.org/10.1086/514610
  20. Zhang SL, Han XB, Yue YF. Relationship between HBV viremia level of pregnant women and intrauterine infection: nested PCR for detection of HBV DNA. World J Gastroenterol 1998;4:61-4
  21. Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003;71:360-6 https://doi.org/10.1002/jmv.10493
  22. van Zonneveld M, van Nunen AB, Niesters HGM, de Man RA, Schalm SW, Janssen HLA. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7 https://doi.org/10.1046/j.1365-2893.2003.00440.x
  23. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and postpartum: aspects on vertical transmission. Scand J Infect Dis 2003;35:814-9 https://doi.org/10.1080/00365540310016547
  24. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71 https://doi.org/10.1046/j.1423-0410.2001.00003.x
  25. Kapke GF, Watson S, Sheffler S, Hunt D, Frederick C. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. J Viral Hepat 1997;4:67-75 https://doi.org/10.1046/j.1365-2893.1997.00127.x
  26. Hwang SH, Kim JH, Kang JH, Hur JK, Lee KY, Lee SH, et al. Follow-up of children with chronic hepatitis B virus infection. Korean J Pediatr Infect Dis 2004;11:73-80 https://doi.org/10.14776/kjpid.2004.11.1.73
  27. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Eng J Med 1975;292:771-4 https://doi.org/10.1056/NEJM197504102921503
  28. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46 https://doi.org/10.1093/oxfordjournals.aje.a117321
  29. Kim JH, Seo K, Kim HM. A comparative study for the outcome of perinatal hepatitis B prophylaxis according to the dosages of hepatitis B immunoglobulin. Seoul : Korea Centers for Disease Control and Prevention, 2006
  30. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4 Suppl 1:11-20 https://doi.org/10.1111/j.1365-2893.1997.tb00155.x
  31. Nainan OV, Khristova ML, Byun KS, Xia GL, Taylor PE, Stevens CE, et al. Frequency and significance of hepatitis B virus antibody resistant mutants. Antiviral Ther 2000;5 Suppl 1:30
  32. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006;24:2781-9 https://doi.org/10.1016/j.vaccine.2006.01.007
  33. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80 https://doi.org/10.1056/NEJM199411033311801